| Project/Area Number |
20590546
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
NAGASHIMA Fumio Saitama Medical University, 医学部, 客員准教授 (70348209)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SASAKI Yasutsuna 埼玉医科大学, 医学部, 教授 (20235279)
FUJITA Keniti 埼玉医科大学, 医学部, 講師 (60281820)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2010: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2009: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2008: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
|
|---|
| Keywords | ヒト組織利用研究 / 臨床薬理学 / ゲノム薬理学 / イリノテカン / UGT1A1 / 薬物動態 / 遺伝子多型 / 個別化医療 / 大腸癌 / 副作用 / 塩酸イリノテカン / 用量調節試験 / UGTIA1 / ABCC2 |
|---|
| Research Abstract |
This phase I/II study demonstrates that the recommended doses of irinotecan and infusional 5-fluorouracil in FOLFIRI for Japanese patients with advanced colorectal cancer who do not possess the UDP-glucuronosyltransferase 1A1*28 allele are 180 and 2400mg/m^2, respectively. Toxicities occurring at the recommended doses are manageable in these patients.
|
